The global Patient-Derived Xenograft (PDX) models market is booming, projected to reach $6.33 Billion by 2033, with a 12.5% CAGR. Driven by personalized medicine & oncology drug development, this report analyzes market trends, key players (Charles River Labs, Crown Bioscience), and regional growth across North America, Europe, and Asia-Pacific. Discover insights into PDX models for various tumor types & end-users.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.